Renascience Inc. (TYO:4889)
Japan flag Japan · Delayed Price · Currency is JPY
1,496.00
-171.00 (-10.26%)
May 30, 2025, 3:30 PM JST

Renascience Company Description

Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan.

The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials.

It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions.

The company was incorporated in 2000 and is headquartered in Tokyo, Japan.

Renascience Inc.
Country Japan
Founded 2000
Industry Biotechnology
Sector Healthcare
Employees 4
CEO Keisuke Furuta

Contact Details

Address:
401 Kyodo Building
Tokyo, 103-0023
Japan
Phone 81 3 6262 0873
Website renascience.co.jp

Stock Details

Ticker Symbol 4889
Exchange Tokyo Stock Exchange
Fiscal Year April - March
Reporting Currency JPY
ISIN Number JP3981100005
SIC Code 2834

Key Executives

Name Position
Keisuke Furuta Chief Executive Officer